Chemometec A/S (CHEMM.CO) Stock Price
Chemometec A/S Price
Revenue has compounded at 17.9% per year over the past 19 years to 511.06 M DKK. Earnings per share have grown at 33.4% per year over the last 19 years. Chemometec A/S's net margin stands at 39.5%, up from 37.2% several years earlier. Chemometec A/S currently offers a dividend yield of about 1.22%. The payout ratio is around 58% of earnings. Analysts set a median price target of 900.15 DKK, implying 56.3% above the current price. Of 12 analysts, 11 rate the stock a buy — an overall Buy consensus.
Chemometec A/S stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Chemometec A/S business model & stock analysis
Frequently asked questions about Chemometec A/S
The business model of Chemometec A/S is focused on providing advanced solutions for cellular analysis and diagnostics. The company specializes in developing and manufacturing instruments that enable users to quantify and analyze cells for various purposes, such as cell counting, size measurement, viability assessment, and cell cycle analysis. Chemometec A/S's innovative technologies and products cater to a wide range of industries, including biopharmaceuticals, life sciences research, clinical diagnostics, and industrial manufacturing. With a strong emphasis on accuracy, reliability, and user-friendliness, Chemometec A/S aims to support its customers in improving their research outcomes and diagnostic capabilities.
Chemometec A/S is primarily active in the biotechnology and life sciences industries.
The main competitors of Chemometec A/S in the market are Beckman Coulter, Inc., Sysmex Corporation, and Becton, Dickinson and Company.
Chemometec A/S is a Danish biotechnology company founded in 1997. With headquarters in Allerød, Denmark, the company specializes in developing and manufacturing innovative instruments and software solutions for cell counting and analysis. Chemometec A/S has established itself as a leading provider of automated cell counters, offering high-quality and reliable products to the global scientific community. The company has garnered significant recognition for its unique imaging technology and advanced image analysis algorithms. Over the years, Chemometec A/S has expanded its product portfolio, ensuring accurate cell counting and viability assessment, particularly in the fields of hematology, microbiology, and life sciences.
Some significant milestones achieved by Chemometec A/S include the development and commercialization of their flagship product, the NucleoCounter® system, which revolutionized cell counting and viability analysis in life science research and industry. The company also expanded its product portfolio with the introduction of the NucleoCassette™ and NucleoView™ software, enhancing the efficiency and accuracy of cell analysis further. Chemometec A/S successfully established a global presence, with offices and distributors in key markets worldwide, consolidating its position as a leading provider of innovative solutions for cell analysis. Through continuous investment in research and development, the company continues to deliver groundbreaking technologies to support scientific advancements.
Chemometec A/S is primarily present in several countries and regions worldwide. The company operates in various regions, including Europe, North America, Asia-Pacific, and the Middle East. Some specific countries where Chemometec A/S has a significant presence are Denmark, the United States, China, Germany, India, Japan, and many others. With its global reach, Chemometec A/S aims to serve customers and expand its market presence across different economies.
Chemometec A/S represents strong values and a clear corporate philosophy. The company prioritizes innovation, scientific excellence, and customer satisfaction. With a focus on providing advanced solutions for cell counting and analysis, Chemometec A/S is committed to delivering accurate, reliable, and user-friendly products. They strive to empower researchers and laboratories with cutting-edge technologies that enhance efficiency and productivity. By continuously investing in research and development, Chemometec A/S ensures that their customers have access to the latest advancements in cell analysis. With their commitment to quality and customer-centric approach, Chemometec A/S aims to be a trusted partner in the field of life sciences.
Analysts currently set an average price target of 883.58 DKK for the Chemometec A/S stock (median: 900.15 DKK), implying +53.4 % versus the latest price. The consensus is based on 12 analyst ratings.
12 analysts currently rate the Chemometec A/S stock: 11 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the Chemometec A/S share trades at 77.05 EUR (576.00 DKK).
The Chemometec A/S share (CHEMM.CO) is listed on 6 stock exchanges, including: London (0DZ0.L), Frankfurt (CHY.F), München (CHY.MU), Düsseldorf (CHY.DU), Kopenhagen (CHEMM.CO).
Chemometec A/S is a Danish biotech company that offers innovative solutions and products for cell analysis in the fields of Hematology, Oncology, and Stem Cell Research. Their core product is the NucleoCounter platform, which includes automated cell counters with patented technology for precise counting and sizing of cells. The company serves various customers, including research institutions, clinical labs, hospitals, biotech and pharma companies, and contract research organizations. They aim to provide solutions that help customers achieve their scientific and clinical goals faster, more reliably, and at a lower cost.
The revenue of Chemometec A/S is 511.06 M DKK. This figure is based on current financial data and reflects the company's business performance.
The profit of Chemometec A/S is 201.84 M DKK. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Chemometec A/S is currently 49.64. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Chemometec A/S stock.
The price-to-sales ratio (P/S) of Chemometec A/S is currently 19.60. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Chemometec A/S stock.
The Eulerpool Quality Score for Chemometec A/S is 6/10.
The ISIN of Chemometec A/S is DK0060055861. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Chemometec A/S is A0MS80. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Chemometec A/S is CHEMM.CO. The ticker symbol is used to trade Chemometec A/S shares on the stock exchange.
Chemometec A/S stock
Chemometec A/S Peer Group
Chemometec A/S Ticker
Chemometec A/S FIGI
All fundamentals and in-depth analysis of Chemometec A/S
Our stock analysis for Chemometec A/S stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Chemometec A/S. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.